Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 %~* Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5%~* Body mass index (BMI) 18.5-40 kg/m\^2~* Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator)~Exclusion Criteria:~* Impaired liver function~* Impaired renal function~* Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure~* Any clinically significant abnormal ECG (electrocardiogram)~* Uncontrolled treated/untreated hypertension~* Recurrent severe hypoglycaemia as judged by the Investigator~* Active hepatitis B and/or active hepatitis C~* Positive human immunodeficiency virus (HIV) antibodies~* Known or suspected allergy to trial product(s) or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).